Health Care · Biological Products, (No Diagnostic Substances)

FENC FENNEC PHARMACEUTICALS INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1211583192 filings
Russell 2000

FENC at a glance

FENNEC PHARMACEUTICALS INC. (FENC, SEC CIK 1211583) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on September 17, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), FENNEC PHARMACEUTICALS INC. (FENC) reported revenue of $44.6 million (down 6.1% from FY2024) and a net loss of $9.7 million. Diluted EPS was -$0.34.
  • As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding FENNEC PHARMACEUTICALS INC. (FENC) shares worth $51.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Brughera Marco Maria on November 13, 2026 of 20,000 shares at $12.00 per share.
  • In the last 90 days, FENC insiders reported 0 open-market purchases ($0) and 5 open-market sales ($1.6M) on Form 4, a net sale of $1.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$44.6M
−6.1% vs prior year
Insiders · 90 days
0 buys · 5 sells
Net −$1.6M
13F holders
21 funds
$51.8M · +0 vs prior quarter
Latest 8-K
Sep 17, 2026
Current report

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $19,608, up $7,146 YoY, including PEDMARK sales $19,425, up 56% from $12,462
  • Cost of product sales margin 4% vs 5% YoY, driven by manufacturing and inventory efficiencies
  • Best performer: PEDMARK product sales, $19,425, up $6,963 YoY; only commercial product disclosed
  • Cash $48,684 vs $36,788 at December 31, 2025; operating cash flow $9,111 vs $(6,511)
  • Outlook: Japan registration strategy and partnering discussions ongoing; additional European launches planned in 2026

Risk Factors

  • No material changes from 10-K risk factors disclosed this quarter
  • Carried-forward business risk: disclosed risks could impair future growth prospects
  • Carried-forward financial risk: disclosed risks could adversely affect financial condition
  • Carried-forward operating risk: disclosed risks could harm results of operations

AI summary of the FENC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Sep 17, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Phase 2 STS-J01 met its primary endpoint, with ASHA-defined hearing loss at 24.0% versus 56.4% historical benchmark
  • 95.8% objective tumor response rate supports six-hour PEDMARK administration without apparent cisplatin antitumor interference
Filed Jun 10, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All five director nominees re-elected, preserving board continuity through the next annual meeting
  • Haskell & White LLP appointment approved with 26,091,716 votes, confirming auditor oversight
Filed May 22, 2026Full analysis →

Item 8.01: Other Events

  • New PEDMARK research to be presented at ASCO 2026
  • Data spans multiple patient populations and tumor types

AI summaries of FENC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for FENC

Don't miss the next FENC filing

  • Alerts as it files. A push when FENC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut FENC, by share count.
  • Ask anything. An AI agent that reads every FENC filing and answers with sources.

FENC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Brughera Marco MariaMNov 13, 2026$2.11
Brughera Marco MariaMNov 13, 2026-
Brughera Marco MariaSellNov 13, 2026$12.00
Hackman Jeffrey S.AOct 31, 2026-
Sayad Pierre SargisAOct 31, 2026-
Cioffi Christiana MarieAOct 31, 2026-
Andrade RobertAOct 31, 2026-
Evans Terry LAOct 31, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$21.3M$47.5M$44.6M
Gross Profit$20.0M--
Operating Income-$12.8M$2.6M-$6.3M
Net Income--$436K-$9.7M
Gross Margin94.1%--
Op. Margin-60.1%5.4%-14.1%
Net Margin--0.9%-21.8%
Balance Sheet
Total Assets$26.9M$44.9M$70.6M
Equity--$5.9M$35.5M
ROE-7.4%-27.5%
Per Share
EPS$-0.60$-0.02$-0.34
Cash Flow
Operating CF-$17.1M$27.0M-$12.5M

Source: XBRL data in FENNEC PHARMACEUTICALS INC. (FENC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate FENC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
FENC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202621$51.8M
Q2 202621$44.9M
Q1 202618$21.7M
Q4 202519$26.6M
Q3 202521$29.9M
Q2 202520$26.2M
Q1 202514$11.7M
Q4 20249$9.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 143 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

FENC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 16, 2026--
10-QNov 12, 2026Analysis
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 1, 2026--
4Oct 1, 2026--
4Oct 1, 2026--
4Oct 1, 2026--
4Oct 1, 2026--
8-KSep 17, 2026Analysis-
4Sep 16, 2026--
4Sep 1, 2026--
4Aug 31, 2026--
4Aug 31, 2026--
4Aug 31, 2026--
4Aug 31, 2026--
4Aug 31, 2026--

Related Health Care companies

All Health Care →

FENC SEC filings: frequently asked questions

Are FENC insiders buying or selling?

In the last 90 days, FENNEC PHARMACEUTICALS INC. (FENC) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $1.6 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold FENC stock?

As of September 30, 2026, the largest FENNEC PHARMACEUTICALS INC. (FENC) holders among the 13F filers tracked by SignalX were BlackRock ($21.7 million), Vanguard Capital Management LLC ($8.9 million), State Street Corp ($4.5 million), Morgan Stanley ($3.0 million), Vanguard Portfolio Management LLC ($2.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was FENC's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), FENNEC PHARMACEUTICALS INC. (FENC) reported revenue of $44.6 million (down 6.1% from FY2024) and a net loss of $9.7 million. Diluted EPS was -$0.34. The figures come from the XBRL data in the 10-K.

What did FENC report in its latest 8-K?

FENNEC PHARMACEUTICALS INC. (FENC) filed an 8-K on September 17, 2026. Phase 2 STS-J01 met its primary endpoint, with ASHA-defined hearing loss at 24.0% versus 56.4% historical benchmark.

What are the latest FENC SEC filings?

FENNEC PHARMACEUTICALS INC. (FENC) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on September 17, 2026 and a Form 4 insider filing on November 16, 2026.

What is FENC's SEC CIK number?

FENNEC PHARMACEUTICALS INC. (FENC)'s SEC Central Index Key (CIK) is 1211583. EDGAR lists every FENC filing under that number.

Ask anything about FENC

The research agent reads FENC's filings, financials, insider trades and 13F holders, then answers with sources.